Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846866 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT06846866 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 74 participants.
The verdict
NCT06846866, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
Interventions
- DRUG Moxifloxacin
- DRUG BMS-986419
- DRUG BMS-986419 Matching Placebo
- DRUG Moxifloxacin Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2025-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846866
The ClinicalTrials.gov registry entry for NCT06846866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT06846866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06846866 about?
NCT06846866 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants". The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
What is the current status of trial NCT06846866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2025-02-27. Estimated completion is 2025-10-21.
What interventions are being tested in trial NCT06846866?
The interventions under investigation include: Moxifloxacin (DRUG), BMS-986419 (DRUG), BMS-986419 Matching Placebo (DRUG), Moxifloxacin Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT06846866?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.